These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30963763)

  • 1. Targeting the Thioredoxin System as a Strategy for Cancer Therapy.
    Bian M; Fan R; Zhao S; Liu W
    J Med Chem; 2019 Aug; 62(16):7309-7321. PubMed ID: 30963763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Thioredoxin System for Cancer Therapy.
    Zhang J; Li X; Han X; Liu R; Fang J
    Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
    Tonissen KF; Di Trapani G
    Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
    Zhang J; Yao J; Peng S; Li X; Fang J
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The thioredoxin system and cancer therapy: a review.
    Mohammadi F; Soltani A; Ghahremanloo A; Javid H; Hashemy SI
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):925-935. PubMed ID: 31367788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thioredoxin-dependent system. Application of inhibitors.
    Jastrząb A; Skrzydlewska E
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):362-371. PubMed ID: 33356659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the potential of thioredoxin reductase inhibitors for cancer therapy.
    Urig S; Becker K
    Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioredoxin reductase inhibitors: a patent review.
    Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
    Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibitors of mammalian thioredoxin reductase.
    Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
    Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of thioredoxin system in cancer: strategy for cancer therapy.
    Jia JJ; Geng WS; Wang ZQ; Chen L; Zeng XS
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):453-470. PubMed ID: 31079220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thioredoxin system modulation by plant and fungal secondary metabolites.
    Dal Piaz F; Braca A; Belisario MA; De Tommasi N
    Curr Med Chem; 2010; 17(5):479-94. PubMed ID: 19941471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiol antioxidant thioredoxin reductase: A prospective biochemical crossroads between anticancer and antiparasitic treatments of the modern era.
    Joardar N; Guevara-Flores A; Martínez-González JJ; Sinha Babu SP
    Int J Biol Macromol; 2020 Dec; 165(Pt A):249-267. PubMed ID: 32961182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A diterpenoid derivate compound targets selenocysteine of thioredoxin reductases and induces Bax/Bak-independent apoptosis.
    Liu J; Mu C; Yue W; Li J; Ma B; Zhao L; Liu L; Chen Q; Yan C; Liu H; Hao X; Zhu Y
    Free Radic Biol Med; 2013 Oct; 63():485-94. PubMed ID: 23732520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells.
    Liang YW; Zheng J; Li X; Zheng W; Chen T
    Eur J Med Chem; 2014 Sep; 84():335-42. PubMed ID: 25036792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Mammalian Thioredoxin Reductase Inhibitors.
    Arnér ESJ
    Handb Exp Pharmacol; 2021; 264():289-309. PubMed ID: 32767140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Anticancer Activity of Auranofin.
    Onodera T; Momose I; Kawada M
    Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
    Liu Y; Li Y; Yu S; Zhao G
    Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B5, a thioredoxin reductase inhibitor, induces apoptosis in human cervical cancer cells by suppressing the thioredoxin system, disrupting mitochondrion-dependent pathways and triggering autophagy.
    Shao FY; Du ZY; Ma DL; Chen WB; Fu WY; Ruan BB; Rui W; Zhang JX; Wang S; Wong NS; Xiao H; Li MM; Liu X; Liu QY; Zhou XD; Yan HZ; Wang YF; Chen CY; Liu Z; Chen HY
    Oncotarget; 2015 Oct; 6(31):30939-56. PubMed ID: 26439985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
    Kłossowski S; Muchowicz A; Firczuk M; Swiech M; Redzej A; Golab J; Ostaszewski R
    J Med Chem; 2012 Jan; 55(1):55-67. PubMed ID: 22128876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.